Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000025 USD | +2,400.00% | 0.00% | +2,400.00% |
Valuation
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Capitalization 1 | 24.21 | 9.523 | 8.578 | 7.89 | 6.776 | 13.35 |
Enterprise Value (EV) 1 | 38.75 | 28.62 | 26.99 | 17.69 | 17.21 | 29.28 |
P/E ratio | -6.76 x | -0.82 x | -0.78 x | -0.26 x | 2.55 x | -1.03 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.18 x | 0.09 x | 0.1 x | 0.1 x | 0.11 x | 0.27 x |
EV / Revenue | 0.29 x | 0.28 x | 0.31 x | 0.22 x | 0.27 x | 0.59 x |
EV / EBITDA | 69.8 x | -14.5 x | -3.86 x | -1.22 x | 5.32 x | -3.41 x |
EV / FCF | -1.95 x | 45.6 x | 2.81 x | -15.8 x | -2.22 x | -11.4 x |
FCF Yield | -51.3% | 2.19% | 35.5% | -6.34% | -45.1% | -8.81% |
Price to Book | -5.06 x | -0.76 x | -0.3 x | -0.28 x | -0.28 x | -0.41 x |
Nbr of stocks (in thousands) | 13,835 | 14,651 | 15,315 | 32,875 | 33,217 | 33,386 |
Reference price 2 | 1.750 | 0.6500 | 0.5601 | 0.2400 | 0.2040 | 0.4000 |
Announcement Date | 3/15/17 | 4/2/18 | 8/25/20 | 8/25/20 | 3/29/21 | 4/15/22 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Net sales 1 | 132.5 | 102.2 | 88.11 | 79.67 | 64.44 | 50.04 |
EBITDA 1 | 0.555 | -1.972 | -6.983 | -14.45 | 3.235 | -8.582 |
EBIT 1 | -1.572 | -3.432 | -7.832 | -15.11 | 2.77 | -8.913 |
Operating Margin | -1.19% | -3.36% | -8.89% | -18.96% | 4.3% | -17.81% |
Earnings before Tax (EBT) 1 | -3.159 | -10.83 | -10.66 | -18.84 | 3.166 | -12.87 |
Net income 1 | -3.477 | -10.97 | -10.76 | -18.93 | 3.185 | -12.87 |
Net margin | -2.62% | -10.74% | -12.21% | -23.76% | 4.94% | -25.71% |
EPS 2 | -0.2587 | -0.7907 | -0.7159 | -0.9244 | 0.0800 | -0.3900 |
Free Cash Flow 1 | -19.86 | 0.6279 | 9.587 | -1.122 | -7.766 | -2.579 |
FCF margin | -14.99% | 0.61% | 10.88% | -1.41% | -12.05% | -5.15% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/15/17 | 4/2/18 | 8/25/20 | 8/25/20 | 3/29/21 | 4/15/22 |
Balance Sheet Analysis
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|
Net Debt 1 | 14.5 | 19.1 | 18.4 | 9.8 | 10.4 | 15.9 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 26.19 x | -9.685 x | -2.636 x | -0.6785 x | 3.225 x | -1.856 x |
Free Cash Flow 1 | -19.9 | 0.63 | 9.59 | -1.12 | -7.77 | -2.58 |
ROE (net income / shareholders' equity) | 46.5% | 126% | 52.8% | 67.4% | -12.2% | 45.5% |
ROA (Net income/ Total Assets) | -2.01% | -6.32% | -16.8% | -48.2% | 12.6% | -46% |
Assets 1 | 173.2 | 173.7 | 64.19 | 39.23 | 25.33 | 27.96 |
Book Value Per Share 2 | -0.3500 | -0.8600 | -1.870 | -0.8500 | -0.7400 | -0.9600 |
Cash Flow per Share 2 | 0.3500 | 0.4300 | 0.1500 | 0.0500 | 0.0600 | 0.0400 |
Capex 1 | 0.51 | 0.04 | 0.13 | 0.01 | 0 | 0 |
Capex / Sales | 0.38% | 0.04% | 0.15% | 0.02% | 0.01% | 0% |
Announcement Date | 3/15/17 | 4/2/18 | 8/25/20 | 8/25/20 | 3/29/21 | 4/15/22 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+2,400.00% | 836 | |
+76.43% | 5.87B | |
+2.76% | 988M | |
+46.03% | 955M | |
+2.49% | 669M | |
-.--% | 600M | |
-2.15% | 593M | |
+10.28% | 536M | |
-.--% | 500M | |
-2.10% | 470M |
- Stock Market
- Equities
- MSLP Stock
- Financials MusclePharm Corporation